GlassScriptPhysician profile
Todd M Leleux
NPI 1881917433
$5,100.96
in general payments reported to CMS, 2019-2025
20 companies · $2,509 in 2025
The $2,509 reported for 2025 was more than what 92% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $65.47 · 2021: $51.41 · 2022: $312 · 2023: $680 · 2024: $1,483 · 2025: $2,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.26 |
| Education | $384.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,265.40 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $921.10 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $395.56 | 2020-2025 | |
| Abbvie INC. | $336.47 | 2022-2025 | |
| Galderma Laboratories, L.P. | $331.65 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $255.37 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $231.04 | 2024-2025 | |
| Leo Pharma INC. | $182.16 | 2023-2025 | Adbry |
| Dermavant Sciences, INC. | $159.36 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $156.86 | 2024-2025 | Zoryve |
| Ucb, INC. | $151.06 | 2025 | Bimzelx |
| Incyte Corporation | $150.47 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $139.39 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $108.40 | 2022-2023 | Sotyktu |
| Organon LLC | $107.51 | 2025 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $96.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.74 | 2024 | Cyltezo |
| Amgen INC. | $35.27 | 2020-2023 | |
| Almirall LLC | $15.97 | 2024 | Klisyri |
| Mallinckrodt Hospital Products INC. | $13.20 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Leleux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.